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Background: Human immunodeficiency virus type 1 (HIV-1) Gag is the main structural protein that mediates the
assembly and release of virus-like particles (VLPs) from an infected cell membrane. The Gag C-terminal p6 domain
contains short sequence motifs that facilitate virus release from the plasma membrane and mediate incorporation
of the viral Vpr protein. Gag p6 has also been found to be phosphorylated during HIV-1 infection and this event
may affect virus replication. However, the kinase that directs the phosphorylation of Gag p6 toward virus replication
remains to be identified. In our present study, we identified this kinase using a proteomic approach and further
delineate its role in HIV-1 replication.
Results: A proteomic approach was designed to systematically identify human protein kinases that potently interact
with HIV-1 Gag and successfully identified 22 candidates. Among this panel, atypical protein kinase C (aPKC) was found
to phosphorylate HIV-1 Gag p6. Subsequent LC-MS/MS and immunoblotting analysis with a phospho-specific antibody
confirmed both in vitro and in vivo that aPKC phosphorylates HIV-1 Gag at Ser487. Computer-assisted structural
modeling and a subsequent cell-based assay revealed that this phosphorylation event is necessary for the interaction
between Gag and Vpr and results in the incorporation of Vpr into virions. Moreover, the inhibition of aPKC activity
reduced the Vpr levels in virions and impaired HIV-1 infectivity of human primary macrophages.
Conclusion: Our current results indicate for the first time that HIV-1 Gag phosphorylation on Ser487 is mediated by
aPKC and that this kinase may regulate the incorporation of Vpr into HIV-1 virions and thereby supports virus infectivity.
Furthermore, aPKC inhibition efficiently suppresses HIV-1 infectivity in macrophages. aPKC may therefore be an
intriguing therapeutic target for HIV-1 infection.
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Human immunodeficiency virus type 1 (HIV-1), a causa-
tive agent of AIDS, is an intracellular parasite that has
evolved to invade complex human systems and utilize its
host machinery for its proliferation. A dynamic interplay
between HIV-1 and its human host systems plays a
crucial role in promoting virus replication. The identifi-
cation of the host factors required for viral infection can* Correspondence: aryo@yokohama-cu.ac.jp
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reproduction in any medium, provided the orprovide further insights into the nature of HIV-1 replica-
tion pathways and assist with identifying new targets for
anti-viral therapies. Recent studies have revealed that
host factors are involved in the post-translational modifi-
cation of viral proteins, such as phosphorylation and
ubiquitination, thereby regulating HIV-1 replication and
pathogenicity [1-3].
The gag gene of HIV-1 encodes both structural and
functional proteins essential for the assembly and release
of enveloped virus-like particles [4]. In the infected cell,
Gag is synthesized as a 55-kDa polyprotein and assembled
into spherical immature particles at plasma membrane.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and are released from the host cell via budding, the virus-
encoded protease becomes activated and cleaves Gag into
its functional subdomains, matrix (MA, p17), capsid (CA,
p24), and nucleocapsid (NC, p7), as well as several shorter
segments: SP1 (spacer peptide 1), SP2, and p6. This pro-
teolytic maturation in tandem with the incorporation of
viral enzymes and accessory proteins into virions results
in the acquisition of HIV-1 infectivity [5-8].
Retroviral assembly can be subdivided into distinct
stages of Gag membrane targeting, virus bud formation
and induction of membrane curvature, and release of
the newly assembled virus bud through a membrane
fission event. HIV-1 budding from the cell surface de-
pends on viral late domains within Gag p6 [9]. Two late
domains have been identified within p6, the PTAP and
LYPXnL motifs. The PTAP motif binds the cellular pro-
tein Tsg101 [10,11], whereas the LYPXnL motif is the
docking site for Alix/AIP-1 [12,13]. Tsg101 functions in
HIV-1 budding as a member of the Endosomal Sorting
Complex Required for Transport-1 (ESCRT-I), which
initiates the sorting of surface proteins into late endo-
somal compartments known as multivesicular bodies
(MVB) [14,15]. Alix, ALG-2 interacting protein, func-
tions in endosomal metabolism, promotes viral bud-
ding by interconnecting HIV-1 Gag with the ESCRT-III
CHMP4 proteins [16,17].
Another important domain within Gag p6 is the
C-terminal LXXLF domain. Interestingly, both the Leu486
and Leu491 residues in this motif are highly conserved
and together with the downstream Phe492, comprise the
LXXLF binding domain for the HIV-1 accessory viral pro-
tein R (Vpr) [18,19]. The substitution of residues in this
domain causes a decrease in the Vpr incorporation levels
compared with full-length HIV-1 Gag protein, indicating
that this conserved region is essential for this process.
HIV-1 Vpr is a non-structural protein that is incorpo-
rated into the viral particles and possesses several charac-
teristic features that are known to play important roles in
HIV-1 replication and disease progression. Vpr mediates
multiple functions, including the nuclear import of the
HIV-1 pre-integration complex, G2 cell cycle arrest, the
transactivation of both viral replication and host genes,
and the induction of apoptosis [20]. Vpr interacts with the
LXXLF binding domain of Gag p6 and is thereby pack-
aged into the virus particles. Virion-incorporated Vpr is
known to positively regulate the infection of non-dividing
cells and enhance virus production in macrophages and in
resting T cells. However, it remains elusive whether and
how Vpr incorporation is indeed regulated. Furthermore,
although p6 has been shown to be post-translationally
modified by phosphorylation [2,21,22], it is unknown
whether this phosphorylation event has any functional
relevance to Vpr incorporation and HIV-1 infectivity.In our current study, we utilized an in vitro high-
throughput protein-protein interaction assay using full-
length HIV-1 Gag and host protein kinases synthesized
by the wheat germ cell-free protein production system
in an attempt to identify the kinase (s) that directs the
phosphorylation of Gag p6 to promote virus replication.
We here report that atypical protein kinase C (aPKC) is
a functional interactor of HIV-1 Gag and facilitates viral
infectivity by promoting the incorporation of Vpr into
virions. We provide evidence that Gag Ser487 (p6 Ser40)
is phosphorylated by aPKC, and that this phosphory-
lation is essential for p6-Vpr interactions and the re-
sultant Vpr incorporation within viral particles. Using
computer-assisted structural modeling, we further ex-
plore the biological significance of the phosphorylation
of Gag-p6 Ser487 by aPKC for the physiological inter-
action between Gag and Vpr. Our current study sheds
new light on the molecular link between Gag phospho-
rylation and viral infectivity through the incorporation
of Vpr into virions.
Results
aPKC binds and phosphorylates HIV-1 Gag
Our initial goal was to identify host kinases that phos-
phorylate the HIV-1 Gag protein. Because Gag phospho-
rylation is important for its functional role, we focused on
human protein kinases as potential Gag regulators. We
synthesized more than 287 full-length protein kinases
using a wheat germ cell-free protein production system,
and screened them for their association with Gag with
the amplified luminescent proximity homogenous assay
(AlphaScreen) [23]. In this method, the extent of the
protein-protein interaction was measured by assaying the
luminescence intensity (Figure 1A). Full-length Gag and
human protein kinases were synthesized using a wheat
germ cell-free system and subjected to an AlphaScreen
assessment. The binding efficiency of HIV-1 Gag with
each kinase was normalized relative to the luminescent
activity of a control DHFR protein (Figure 1B). When a
relative light unit per cutoff (RLU/Co) ratio of ≥ 3.0 was
used as the threshold, we found that 22 host kinases could
selectively interact with HIV-1 Gag and thus were identi-
fied as primary kinase candidates for the phosphorylation
of HIV-1 Gag (Figure 1B).
Our assay detected Erk2 and PKCβ as Gag interactors
(S/N = 1.76 and 1.17, respectively), both of which have
been already reported to phosphorylate Gag during
HIV-1 infection [2,22,24,25]. This validated our screen-
ing approach. Interestingly, we further found that the
aPKC family kinases, PKCζ and PKCι, could interact
with HIV-1 Gag at a relatively high score (S/N = 3.57
and 3.19, respectively). PKCζ and PKCι share a more
than 70% amino acid identity in entire protein sequence
and 84% in the catalytic domain, and an almost identical
Figure 1 aPKC phosphorylates HIV-1 Gag. (A) Schematic representation of the AlphaScreen based luminescent system used to screen for human
kinases that interact with HIV-1 Gag. Briefly, HIV-1 Gag was incubated with each human protein kinase and protein A-conjugated acceptor beads with
anti-FLAG antibody and streptavidin coated donor beads were added and bound to the tagged substrate. Upon laser excitation, the donor beads
convert ambient oxygen to singlet oxygen. When a molecular interaction occurs between HIV-1 Gag and a particular kinase, singlet oxygen transfers
across to activate the acceptor beads and subsequently emit light at 520–620 nm. (B) HIV-1 Gag interacting kinases identified from a human kinase
protein library. (C) Confocal microscopy analysis of V5-aPKC (Alexa 568) and Gag-Flag (Alexa 488) in 293T cells. (D) Immunoprecipitation of Gag with
aPKC. 293T cells were transfected with Flag tagged Gag and cell lysates were immunoprecipitated with anti-Flag antibody 48 hours later. Samples were
then probed with anti-aPKC and anti-Flag antibodies. Bottom panel shows input for pull-down assay. (E) In vitro phosphorylation of HIV-1 Gag by aPKC.
GST, GST tagged aPKC and Gag proteins were expressed and affinity-purified from wheat germ cell-free extract. aPKC-mediated phosphorylation was
assessed by incubating recombinant GST or GST-Gag with recombinant active GST-aPKC in the presence of [γ-32P] ATP. The reaction products were
analyzed by autoradiography, Coomassie Brilliant Blue (CBB) stain and blotted with GST antibody.
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previously uncharacterized Gag-interacting factor for
further in depth functional analysis.
To better understand the functional relevance of aPKC
in HIV-1 infection, we first examined the subcellular
localization of both HIV-1 Gag protein and aPKC pro-
tein in 293T cells by immunofluorescent analysis. 293T
cells were transfected with Flag tagged HIV-1 Gag and
V5-aPKC expression vector. Gag-Flag displayed a punc-
tate expression pattern in the cytoplasm and a partial
co-localization with aPKC in cytoplasm and plasma
membrane (Figure 1C).
We performed immunoprecipitation analysis and found
that aPKC could bind Gag in cells (Figure 1D). We nextexamined whether aPKC can directly phosphorylate HIV-1
Gag protein in vitro. Recombinant GST-Gag or GST
proteins were expressed and purified from wheat germ
cell-free extract by glutathione sepharose beads and used
as substrates for in vitro kinase assays. aPKC was found to
phosphorylate GST-Gag but not GST, with a prominent
auto-phosphorylation of aPKC also observed (Figure 1E).
These data together indicate that aPKC binds and phos-
phorylates HIV-1 Gag.
aPKC phosphorylates the Ser487 residue of HIV-1 Gag
We next sought to determine the sites of aPKC phos-
phorylation in HIV-1 Gag. GST-Gag was incubated with
recombinant aPKC for their phosphorylation and this
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tial phosphorylation site analysis was performed using
the data dependent of tandem matrix-assisted laser
desorption Ionization-time of flight mass spectrometry
(MALDI-TOF/TOF-MS), followed by in depth analysis
with selected peptides through data collection. Fragmen-
tation of this peptide by MS/MS produced a spectrum
through which we identified one of the b-ions and 10 of
the y-ions matching the sequence QEPIDKELYPLTpSLR.
Tandem mass spectra of the signals at m/z 1881.95,
m/z 1783.95(neutral loss) and m/z 1801.97 revealed se-
quences corresponding to the unmodified, mono- phos-
pho peptide of Gag-p6 (QEPIDKELYPLTpSLR; Figure 2).
Furthermore, a Mascot search result identified the se-
quence QEPIDKELYPLTpSLR (score 73). The Ser487
site was found to be located at Ser40 of Gag-p6 domain
in close proximity to both LYPXnL and LXXLF motif.
Based on our MS analysis, we constructed a GST-tagged
p6 and its site-directed mutant GST-p6-Ser487Ala (S487A)
and GST-p6-Ser461Ala (S461A) as a negative control.
Subsequent in vitro kinase assay results demonstrated that
GST-p6 is phosphorylated by aPKC, but not GST-p6-Figure 2 Identification of the phosphorylated Gag-p6 site. (A) Schema
phosphorylated GST-Gag after trypsin digestion. The red arrow indicates th
aPKC. This is consistent with the mass of the theoretical phosphorylated pe
resulting phosphopeptide was analyzed using MALDI-TOF/TOF MS. Fragme
from the peptide are shown. Tandem mass spectra of m/z 1881.95 signals
(QEPIDKELYPLTpSLR) of Gag-P6.S487A (Figure 3A). These results suggested that aPKC
indeed phosphorylates the Ser487 residue of HIV-1 Gag
in vitro.
To further assess the phosphorylation of Gag at Ser487,
we generated a polyclonal antibody against phosphoryated-
Ser487 (pS487). We initially confirmed the specificity and
sensitivity of the antibody using the AlphaScreen system.
We found that our antibody recognized only Ser487 phos-
phorylated peptides but neither a non-phosphorylated
peptide nor a peptide harboring a Ser487 to Ala sub-
stitution (Figure 3B). We then used this antibody for in
depth cell culture study. 293T cells were transfected with
V5 tagged wild type aPKC or a kinase-negative mutant
(aPKC-Kn), together with wild type Gag-Pol. A marked
increase in the level of Gag phosphorylation at Ser487 was
observed in cells expressing the wild type aPKC, whereas
there was no obvious increase in the amounts of phos-
phorylation in either aPKC-Kn or mock transfected cells
(Figure 3C). These observations clearly indicate that the
expression of aPKC leads to the phosphorylation of HIV-1
Gag at Ser487 in cells, and that this phosphorylation is
dependent of the kinase activity of aPKC.tic overview of the experimental workflow. (B) MS peptide map of
e 1881.95 Da peak which is unique to the sample treated with active
ptides and the map shows a neutral loss peak at 1783.95. (C) The
nt ions of the b and y-series identified in the tandem mass spectra




Figure 3 aPKC phosphorylates HIV-1 Gag on Ser487. (A) GST-p6, GST-p6S461A or GST-p6S487A proteins were expressed and affinity-purified
from wheat germ cell-free extracts. aPKC-mediated phosphorylation was assessed by incubating recombinant GST-p6, GST-p6S461A or GST-p6S487A
with recombinant active GST-aPKC in the presence of [γ-32P] ATP for 60 min at 37°C. The reaction products were analyzed by autoradiography and
Coomassie Brilliant Blue (CBB) staining. (B) Assessment of phospho-Ser487 antibody specificity and binding efficiency using the AlphaScreen system.
Biotin tagged peptides were incubated with phospho-Ser487 specific antibodies for. The graph shows the luminescence signal intensity which
represents antibody binding efficiency. Each value is the mean of three independent experiments. (C) 293T cells were transfected with wild type
Gag-pol and either V5 tagged wild type aPKC (WT) or kinase-negative aPKC (Kn). Whole-cell extracts were prepared, and equal amounts of proteins for
each sample were separated by SDS-PAGE and subjected to western blot analysis using indicated antibodies. (D) Effects of aPKC inhibitor on the
phosphorylation of Gag-Ser487. 293T cells were transfected with Gag-pol expression vector and cultured in the presence of the indicated concentrations
of aPKC inhibitor. Clarified cell lysates were prepared and equal amounts of proteins were subjected to SDS-PAGE, followed by western blot analysis
using indicated antibodies. Densitometry analysis of the p55Gag (pS487)/p55Gag bands in the western blot is shown in the bottom panel. (E) Effects of
aPKC inhibitor on viability of 293T cells. 293T cells were treated with aPKC inhibitor (2 or 5 μM) or 1 μM Staurosporine (STS) and analysed for cell viability
using trypan blue exclusion at 48 hours. (F) Effects of kinase specific inhibitors on the phosphorylation of Gag-Ser487. 293T cells were transfected with
Gag-pol expression vector and treated with inhibitors against cPKC, AKT, CDK and PI3K. Cell lysates were prepared and analyzed as described in (D).
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HIV-1 Gag at Ser487 is mediated by endogenous aPKC
activity, we employed a myristoylated PKCζ pseudosub-
strate peptide as an aPKC inhibitor. This PKCζ pseu-
dosubstrate peptide mimics the substrate binding site in
PKCζ (113–125) and PKCι (114–126), and suppresses
the activity of endogenous PKCι and PKCζ. HIV-1 Gag-
Pol expression plasmids were transfected into 293T cells
with or without aPKC inhibitor treatment. Immunoblot
analysis revealed that the aPKC inhibitor suppressed
Gag phosphorylation at Ser487. Subsequent titration
analysis demonstrated a dose-dependent inhibitory effect
of the PKCζ pseudosubstrate peptide by showing an
74.9% and 70.4% decrease in Gag phosphorylation at
2 μM and 5 μM doses, respectively (Figure 3D). Note
that at these concentrations the aPKC inhibitor did notaffect the expression levels of endogenous aPKC as well
as a house-keeping protein Vinculin (Figure 3D). Fur-
thermore, cell viability was not prominently affected by
aPKC inhibitor when cells were assessed by trypan blue
exclusion (Figure 3E). Conventional PKC (PKCα, PKCβ),
Akt, CDK and PI3 kinases have been reported previously
to affect HIV-1 replication through their phosphory-
lation of HIV-1 or of host proteins [3,24,27-30]. We thus
also investigated using specific inhibitors whether these
kinases could mediate the phosphorylation of HIV-1
Gag at Ser487. Our results show that neither PKCα nor
PKCβ specific pseudosubstrates affect Gag phospho-
rylation at Ser487 (Figure 3F). Similarly, neither Akt
inhibitor, the CDK inhibitor roscovitine nor the PI3K
inhibitor wortmannin blocked Gag phosphorylation at
Ser487 (Figure 3F). Taken together, these observations
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Gag at Ser487 both in vitro and in vivo.
The phosphorylation of Gag Ser487 facilitates the
interaction between Gag and Vpr
HIV-1 Gag p6 contains a late domain consisting of three
protein binding motifs, PTAP (Tsg101 binding), LYPXnL
(Alix binding) and C-terminal Vpr. Ser487 is located in
the Alix binding motif and is also adjacent to the Vpr
binding motif spanning amino acids 488–492 (Figure 4A).
To obtain structural-based information on Gag phospho-
rylation on Ser487 and how it affects the interaction of
Gag with Alix or Vpr, we conducted computer-assisted
molecular modeling of the Gag p6 domain coupled with
peptides derived from either Alix or Vpr. The models con-
structed in this study included unphosphorylated and
phosphorylated Gag-p6 (amino acids Tyr483-Ser494), and
its Ser/Ala substituted mutant on Ser487 (S487A). Mo-
lecular modeling calculations with thermodynamically op-
timized three dimensional structures showed less than 1 ÅFigure 4 The phosphorylation of Gag at Ser487 facilitates the interac
Gag-p6 sequence indicating the binding motifs, Tsg101, Alix and Vpr, locat
with Alix or Vpr. The structural calculations were undertaken using MOE. Up
wild-type Gag-p6, Gag-p6Ser487A or phosphorylated Gag-p6-Ser487. Botto
wild-type Gag-p6, Gag-p6Ser487A or phosphorylated Gag-p6-Ser487. Bindin
were shown in the bottom tables, where the highly negative value indicatof positional shifts of Cα atoms of Gag-p6 by phosphory-
lation, suggesting no obvious difference in the basic struc-
ture of Gag-p6 irrespective of the phosphorylation status.
Furthermore, binding interface between Gag-p6 and Alix
was not affected by the phosphorylation (Figure 4B, Upper
panels) or Ser/Ala substitution of Gag Ser487 [31-33]. On
the other hands, the binding of Gag-p6 with Vpr was
facilitated since the phosphorylation of Ser487 can create
another hydrogen bond between Gag-p6 and Vpr (Figure 4B,
Lower panels). The Ser487 was predicted to form no hydro-
gen bonds with Vpr in non-phosphorylated state, whereas
the phosphorylated Ser487 could form the hydrogen bond
with Gln44 of Vpr. Consequently, binding energy calculated
with Molecular Operating Environment (MOE) was signifi-
cantly increased by phosphorylation of Ser487 only for the
Gag-p6-Vpr complex (Figure 4B, tables). These data suggest
that the phosphorylation of Gag-p6 on Ser487 could indeed
affect the binding affinity of Gag-p6 with Vpr but not Alix.
Based on our structural modeling results, we next
asked whether the phosphorylation of Gag at Ser487 hastion of Vpr and Gag-p6. (A) Schematic representation of the HIV-1
ed around the Ser487 site. (B) Complex structure models of Gag-p6
per panel shows structural models of the interaction of Alix with
m panel shows structural models of the interaction of Vpr with
g energies of p6 with Alix or Vpr calculated from the structural models
es the stable binding.
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have selected Bimolecular Fluorescence Complementa-
tion (BiFC) system to quantify the Vpr-Gag interaction
in live cells as previously reported [34]. Plasmids
encoding C-terminally KGC-tagged Gag (Gag-KGC) and
N-terminally KGN-tagged Vpr (KGN-Vpr) were transfectedFigure 5 The phosphorylation of Gag at Ser487 promotes the incorpo
complementation (BiFC) of 293T cells expressing Gag-KGC and KGN-Vpr (up
and Gag-KGC or Gag (S487A)-KGC, were harvested and analyzed by flow cy
Results represent the means of three independent experiments. The cells w
phosphorylation of Gag at Ser487 promotes interaction of Vpr with Gag. H
in presence of 5 μM aPKC inhibitor or DMSO, followed by pulldown with F
panel shows input for pulldown assay. (C) Differential effect of Gag Ser487
were transfected with GFP-tagged Gag (Gag-WT) or with the Ser487 point
Vpr expression vectors. Cells and VLPs were collected at 24 hours post-tran
subjected to western blot analysis. (D) aPKC-mediated Gag phosphorylatio
transiently transfected with Gag-Pol, either Flag-tagged Vpr (WT) or Gln44 p
kinase-negative aPKC (Kn). Cell lysates and VLPs were collected 24 hours po
phosphorylation of Gag-pol-Ser487 is required for Vpr incorporation into H
with Gag-Pol (WT) or with the Ser487 point mutated Gag-Pol (S487A). The
24 hours. Cell lysates and VLPs were collected and subjected to western bland evaluated for BiFC signal by flow cytometry (Figure 5A).
Flow cytometry analysis revealed that the interaction of
Vpr with Gag-Ser487Ala mutant was reduced as com-
pared with wild-type Gag (Figure 5A). To further assess
whether the phosphorylation of Gag at Ser487 provides
another hydrogen bond with Vpr Gln44 to facilitate Gag-ration of Vpr into HIV-1 virions. (A) Bimolecular fluorescence
per panel). 293T cells were transfected with KGN-Vpr (WT or Q44E)
tometry to determine the BiFC signal at 48 hours post-transfection.
ere harvested and subjected to western blot analysis. (B) The
A-tagged Vpr was co-transfected with Flag tagged Gag into 293T cells
lag-beads and immunoblotting with indicated antibodies. Bottom
phosphorylation on Alix and Vpr incorporation into VLPs. 293T cells
mutated Gag (Gag-S487A), with either HA-tagged Alix, or HA-tagged
sfection, and their protein extracts were resolved using SDS-PAGE and
n at Ser487 facilitates Vpr incorporation into virions. 293T cells were
oint mutated Vpr (Q44E), and with either V5-tagged aPKC (WT) or
st-transfection and subjected to western blot analysis. (E) The
IV-1 virions. 293T cells were transfected with Flag-tagged Vpr and either
transfected 293T cells were treated with DMSO or aPKC inhibitor for
ot analysis.
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BiFC analysis. Results demonstrated that Vpr Q44E mu-
tant exhibited weker interactions to Gag and Gag S487A
as compared with wild type Vpr (Figure 5A). We further
found that aPKC inhibitor suppressed the interaction bet-
ween Gag-Flag and HA-Vpr in imunoprecipitation ana-
lysis (Figure 5B).
The phosphorylation of Gag at Ser487 affects Vpr
incorporation into virions and viral infectivity
We next examined whether the phosphorylation of Gag at
Ser487 has any effects on the incorporation of Vpr into
HIV-1 virus like particles (VLP). As shown in Figure 4B,
we found no distinct changes in the incorporation of Alix
into VLPs regardless of a Ser/Ala substitution at Gag
Ser487 in 293T cells. However, Vpr incorporation into
VLP was significantly decreased in cells transfected with
the Gag-Ser487Ala mutant as compared with cells trans-
fected with wild-type Gag (Figure 5C). Hence, it is plaus-
ible that the phosphorylation of Gag at Ser487 may have
an important role in its interaction with Vpr thereby af-
fecting the Vpr incorporation into VLPs.
To further explore the relevance of Gag phosphory-
lation to HIV-1 replication, we examined whether aPKC
kinase activity is necessary to regulate Vpr incorporation
into HIV-1 virions. Gag phosphorylation at Ser487 was
prominently enhanced by wild type aPKC but not kinase
negative mutant aPKC (Kn) (Figure 5D). Concomitantly,
the level of Vpr incorporation into virions was shown to
be paralleled with the Gag phosphorylation status (lane
1 and 2 in Figure 5D). More importantly, virion incor-
poration of Vpr Q44E mutant was much lesser than
wild-type Vpr irrespective of Gag phosphorylation at
Ser487 (lane3 and 4 in Figure 5D). These results suggest
that Gag phosphorylation at Ser487 is indeed affect Vpr
incorporation and this process could be mediated by the
Gln44 residue of Vpr. Although no significant effect of
the Gag-pol S487A mutant on the Vpr expression levels
in cells was evident, the Vpr incorporation level into
VLPs was significantly reduced upon Gag-pol-S487Ala
transfection (Figure 5E). Consistent with this result, the
incorporation of Vpr into VLPs was significantly reduced
in cells treated with the aPKC inhibitor peptide; the Vpr
incorporation efficiency was reduced in aPKC inhibitor
treated cells (Figure 5E). These data indicate that aPKC
can enhance the incorporation of Vpr into HIV-1 virions.
It has been well established that Vpr incorporation
into HIV-1 virions augments viral infectivity in macro-
phages [5,6,35-37]. We thus assessed whether aPKC
affects HIV-1 infectivity by increasing Vpr incorporation
into virions. We hypothesized that if the Gag phos-
phorylation at Ser487 by aPKC was beneficial for HIV-1
infection in this way, aPKC activity would affect wild type
HIV-1 but not a Vpr-null virus. To test this, we employedpNL4-3ΔEnv-luc (WT) or pNL4-3ΔEnvΔVpr-luc (Vpr-
null) strains. We then produced the corresponding vi-
ruses with a fusiogenic envelope G glycoprotein of the
vesicular stomatitis virus (VSV-G) in the presence or
absence of aPKC inhibitor in 293T cells (Figure 6A). Im-
munoblotting analysis of VLP demonstrated that the
level of Vpr incorporation was prominently reduced by
treatment with the aPKC peptide inhibitor (Figure 6B).
The infectivity of the generated viruses was tested using
the human monocyte/macrophage cell line MonoMac6.
The aPKC inhibitor-treated WT virus exhibited approxi-
mately 50% less infectivity than the control WT virus
(Figure 6C). The Vpr-null virus showed a 35% reduction
in infectivity compared with the WT virus in the Mono-
Mac6 cells (Figure 6C). However, the primarily low in-
fectivity of the Vpr-null virus was not significantly
affected by the aPKC inhibitor (Figure 6C). aPKC inhibi-
tor did not exhibit obvious cytotoxic effect to MonoMac
6 cells (Figure 6D).
To assess the role of aPKC in multi-round HIV-1 replica-
tion in primary monocyte-derived macrophages (MDMs),
we infected these cells with HIV-189.6, a dual tropic virus,
or HIV-1NLAD8, an R5 tropic virus, in conjunction with
treatments of various concentrations of the aPKC inhibitor
(Figure 7A). The results revealed that the aPKC inhibitor
strongly suppressed the replication of both viruses in a
dose-dependent manner (Figure 7B, C), although there was
no obvious toxicity or growth inhibition in these cells
(Figure 7D). Taken together, these results indicate that the
phosphorylation of Gag by aPKC regulates Vpr incor-
poration and HIV-1 replication in macrophages.
Discussion
We here demonstrate that aPKC is a crucial regulator of
HIV-1 infection via the phosphorylation of Gag-p6 which
enhances the incorporation of Vpr into virions. Our cur-
rent data strongly suggest that Ser487 is the specific phos-
phorylation site on HIV-1 Gag for aPKC and is crucial for
the Gag p6-Vpr interaction that leads to Vpr incor-
poration into viral particles. Furthermore, our current data
demonstrate that an aPKC inhibitor prominently inhibits
HIV-1 replication in primary human macrophages. Hence,
the phosphorylation of Gag by aPKC may well be an
important mechanism through which HIV-1 efficiently in-
fects macrophages and by which an excessive accumula-
tion of the cytotoxic Vpr protein in the host infected cells
is prevented.
The Gag-p6 domain has been identified as the pre-
dominant site of phosphorylation in HIV-1 particles
[22]. Ser487 is a highly conserved residue in this p6
domain among various HIV-1 strains, suggesting that
the phosphorylation of this residue is of fundamental
functional importance. Votteler et al. have demonstrated
that a HIV-1 Gag mutant with a deleted PTAP region
Figure 6 The inhibition of aPKC significantly decreases single-round HIV-1 infection. (A) Schematic representation of the experimental
system. Briefly, 293T cells were either mock treated, or treated with aPKC inhibitor. After 4 hours, these cells were co-transfected with pNL4-3Δenv-luc
or pNL4-3ΔenvΔVpr-luc and with pVSV-G. Viral release was measured through the quantification of p24CA antigen concentration in the culture
supernatants at 48 hours post-transfection. MonoMac6 cells were infected with VSV-G pseudotyped WT and ΔVpr viruses for 48 hours. (B) The VSV-G
pseudotyped WT and ΔVpr stocks generated from pNL4-3Δenv-luc and pNL4-3ΔenvΔVpr-luc with/without aPKC inhibitor treatment were analyzed by
immunoblotting for the incorporation of Vpr into virion particles. (C) Viral infectivity was detected by measuring the luciferase activity in the cell lysates.
Data are mean ± s.e.m. of three independent experiments. (D) Effects of aPKC inhibitors on viability of MonoMac6 cells. MonoMac6 cells were treated
with aPKC inhibitor (2 or 5 μM) or 1 μM Staurosporine (STS) and analyzed for cell viability using trypan blue exclusion at 72 hours. Data are mean ± s.e.m.
of three independent experiments: **p < 0.01, Student’s t-test.
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S487F) shows aberrant core formation and reduced viral
infectivity in TZM-b1 cells [33]. More recently, steady
state affinity analysis using a surface plasmon resonance
sensorgram has revealed that the phosphorylated form
of p6 at Ser487 has a stable binding affinity for cyto-
plasmic membranes [38]. These reports have therefore
revealed that Gag Ser487 is a highly conserved phosphor-
ylation site of likely crucial importance for HIV-1 infec-
tion. On the other hand, Radestock et al. recently reported
in tissue culture experiments that the phosphorylation of
Gag-p6 including Ser487 is dispensable for HIV-1 infecti-
vity. These authors showed that asparagine substitutionsat five serine residues (Ser487, Ser490, Ser494, Ser497 and
Ser498) within the C-terminus of Gag p6 produced no im-
pairment of Gag assembly or virus release and caused only
very subtle deficiencies in viral infectivity in T-cell lines
and in primary lymphocytes [39]. These discrepancies
may be due to different experimental approaches using
different Gag substitution mutants as well as different cell
types. In contrast, our present approach is distinct from
these earlier studies as we initially attempted to identify
the kinases responsible for Gag-p6 phosphorylation and
then explore their role in HIV-1 replication. Our current
results clearly demonstrate that aPKC phosphorylates
Gag-p6 and regulates the interaction of Gag with Vpr for
Figure 7 (See legend on next page.)
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Figure 7 The inhibition of aPKC significantly reduces replication competent HIV-1 infection. (A) Schema of the experimental system using
HIV-1 replication competent HIV-189.6 and HIV-1NLAD-8. Monocytes were isolated from buffy coat from healthy blood donors by positive selection
on Monocyte Enrichment Cocktail and density gradient centrifugation as described in Methods. MDMs were generated by culturing monocytes
with 100 ng/ml granulocyte-macrophage colony-stimulation factor for 5 days before HIV-1 infection. MDMs were infected with 5 ng of p24 from
(B) HIV-189.6 or (C) HIV-1NLAD-8 virus and the levels of p24 capsid released into media during viral replication were assayed over a period of
12 days post infection. Data are the mean ± s.e.m. of three independent experiments: **P < 0.01, Student’s t-test. (D) Effects of aPKC inhibitor on
viability of MDMs. MDMs cells were treated with aPKC inhibitor (2 or 5 μM) or 1 μM Staurosporine (STS) and analysed for cell viability using trypan
blue exclusion at 96 hours. (E) Schematic model of our current study. aPKC phosphorylate HIV-1 Gag at Ser487. This phosphorylation promotes
the interaction between Gag and Vpr, thereby facilitating viral infectivity in macrophages.
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cific effects of aPKC-mediated Gag-p6 phosphorylation
are consistent with the evidence that the substitution of
Gag Ser487 for Ala significantly decreases Vpr incorpor-
ation and viral infectivity. On the other hand, inhibition of
aPKC in cells may have other additional effects on HIV-1
replication cycle rather than Gag phosphorylation for the
Vpr incorporation. To observe the specific effect of aPKC
on Gag phosphorylation, we created Gag and Vpr mutants
devoid of the effect of aPKC and these mutants were less
competent in virus replication. However, aPKC may regu-
late other cellular function directing HIV replication. Al-
though our current data clearly demonstrate a crucial role
of aPKC in Gag Ser487 phosphorylation and interaction
Gag-Vpr to Vpr incorporation, further detailed analyses
may be necessary to clarify the molecular signature of Gag
p6 phosphorylation on multiple stages of the HIV-1 repli-
cation cycle.
We show from our current experiments that Gag
Ser487 phosphorylation has a significant impact on p6-
Vpr binding. Vpr is a non-structural viral protein that is
incorporated into virions and possesses several charac-
teristic features and functions that are known to play im-
portant roles in HIV-1 replication and disease progression
[40]. The presence of a functional Vpr in viral particles
is necessary for the efficient translocation of the pre-
integration complex (PIC) into the nucleus and subse-
quent infection of primary monocytes/macrophages and
other non-dividing cells [5,6]. Vpr also has a crucial role
in viral replication, apoptosis, cell cycle arrest and in
the down-regulation of immune activation [37,41-43].
Many Vpr functions are carried out by virion-associated
Vpr [44], suggesting that the incorporation of Vpr
into virus particles is an important event not only in
HIV-1 replication but also in HIV-1 mediated cyto-
pathogenesis.
Several previous reports have indicated that p6 is phos-
phorylated during HIV-1 infection [2,22]. However, these
studies did not undertake any detailed investigation of
the biological significance of this phosphorylation event
through biochemical or structural analyses. Our current
computer-assisted structural modeling and AlphaScreen
homogenous proximity assays have revealed that the
phosphorylated Gag at Ser487 binds more stably to Vprwhereas there was no significant difference in the inter-
action of Gag-p6 with Alix, consistent with previous
reports [31,32]. The phosphorylation of Ser487 can create
another hydrogen bond between Gag-Ser487 and Vpr-
Gln44. In consistent with this data a previous study indi-
cated that the site specific deletion of Gln44 resulted in
the significant reduction of Vpr incorporation into virions
[34]. We also demonstrate that Gag phosphorylation at
Ser487 affects Vpr incorporation and this process could
be mediated by Gln44 residue of Vpr.
We show in our current study that Gag phosphoryl-
ation on Ser487 itself does not affect the binding affinity
of Gag with Alix. However, resultant Vpr interaction to
Gag may hinder the Alix-Gag interaction at the LYPXnL
motif. This may eliminate Alix from nascent VLP and
impeded its ability to function in HIV-1 release in
PTAP-deficient strains of HIV. On the other hands, Alix
also interacts with the nucleocapsid (NC) domain of
HIV-1 Gag in addition to binding the LYPXnL motif
[45], there by linking Gag to components of ESCRT-III.
Therefore, further analysis is needed to fully understand
the molecular link between Gag phosphorylation and
virus release through the Alix/LYPXnL pathway.
We further explored the physiological significance of
Vpr incorporation into virions. Our current results clearly
demonstrate that the inhibition of aPKC-mediated Vpr
incorporation prominently reduces the viral infectivity in
MDMs. These results together indicate that Gag phos-
phorylation by aPKC plays a crucial role in the HIV-1
infection of macrophages.
aPKC has been demonstrated to be involved in cell po-
larity and migration in a number of study models [46].
During cell migration, aPKC localizes on the leading edge
of the plasma membrane where HIV-1 Gag is also loca-
lized in infected cells. It has been reported in an earlier
study that aPKC is located at an immunological synapse
with potential importance in cell-to-cell viral transfer [47].
It is thus plausible that aPKC may regulate the incorpor-
ation of Vpr into virions at the leading edges or the HIV-1
virological synapse in polarized cells [48]. It would be
interesting to investigate whether aPKC cooperates
with other factors in polarized HIV-1-infected cells
in an additional mechanism to its function in Gag
phosphorylation.
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monstrated that aPKC mediates the NF-κB transcrip-
tional activation required for HIV-1 infection in U937
cells. It is of particular interest that aPKC is a one of the
key regulators of HIV-1 infection. Our present findings
also provide evidence for the involvement of aPKC in
HIV-1 replication by showing that it directly phospho-
rylates Gag on Ser487, and that this phosphorylation
mediates Vpr incorporation into virions. The targeting
of aPKC activity is therefore a potential option as a novel
therapeutic intervention against HIV-1 infection in com-
bination with existing anti-retroviral treatments.
Conclusions
We have identified aPKC as a host protein kinase that
phosphorylates HIV-1 Gag at its Ser487 residue. Com-
puter assisted structural modeling and subsequent bio-
chemical assays revealed that the phosphorylation of Gag
Ser487 enhances the association of Gag with Vpr and
promotes the resultant incorporation of Vpr into virions.
These events facilitate viral infectivity in macrophages.
Hence, aPKC inhibition is a potential new therapeutic
approach against HIV-1 infection in human macrophages.
Methods
Viral DNA constructs and plasmids
The HIV-1 reporter virus vectors pNL4-3ΔEnv-Luc and
pNL4-3ΔEnvΔVpr-Luc were provided by Akifumi Takaori-
Kondo (Kyoto University, Kyoto, Japan) [50,51]. The HIV-1
recombinant molecular clone pHIV-189.6 and pHIV-1NLAD8
were provided by Akio Adachi (Tokushima University,
Tokushima, Japan). The HIV-1 Gag and HIV-1 p6
(pNL4-3) derived-DNA fragment was generated by
PCR and inserted into the pEU-E01-GST-MCS vector
(Cellfree Sciences, Yokohama, Japan). Using this sub-
cloned plasmid, we generated substitution mutants with
PrimSTAR Max (Takara Bio Inc, Shiga, Japan) and the
following primers for Ser487A,
5’-TTAACTGCGCTCAGATCACTCTTTGGC-3’ and
5’-TCTGAGCGCAGTTAAAGGATACAGTTC-3’. Plas-
mids expressing HIV-1 Gag-Pol were provided by Jun
Komano [52] (National Institute of Infectious Diseases,
Tokyo, Japan). Expression vectors encoding aPKCλ wt
and aPKCλ kn, a kinase-deficient mutant, have been pre-
viously described [53]. C-terminal Flag-tagged p55Gag
(codon-optimized) has been previously described [54].
All the DNA experiments were approved by Gene and
Recombination Experiment Safety Committee at the
Yokohama City University School of Medicine.
Antibodies and other reagents
The anti-p24 (CA) mouse monoclonal antibody (clone
Kal-1) was purchased from Dako (Glostrup, Denmark).
Anti-Flag (M2) and anti-Vinculin mouse monoclonalantibodies were obtained from Sigma (St. Louis, MO).
Anti-PKCι mouse monoclonal antibody was from BD
transduction (Franklin Lakes, NJ). Polyclonal rabbit anti-
Vpr antibody was obtained from the AIDS research and
Reference Reagent Program, National Institute of Allergy
and Infectious Diseases (US National Institute of Health,
Germantown, MD). The peptide specific antibody against
PLT (pS) LRSLFGND (phosphorylated at Ser487 of Gag
peptide from 484 to 495) was generated by Scrum Inc
(Tokyo, Japan). The myristoylated (myr) PKC ζ peptide
inhibitor myr-PKCζ (N-myr-Ser-Ile-Tyr-Arg-Arg-Gly-Ala-
Arg-Arg-Trp-Arg-Lys-Leu-OH) and myr-PKC α and β
(N-myr-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-NH2) were
purchased from Merck (Darmstadt, Germany). Akt inhibi-
tor was obtained from Calbiochem (Darmstadt, Germany),
and the PI3K inhibitor Wortmannin was obtained from
Merck. The Cdk inhibitor roscovitine was purchased from
Promega (Madison, WI). All inhibitors were dissolved in
DMSO and stocks were aliquoted and stored at −60°C
until use. The final concentration of each inhibitor used is
indicated in the figure legends.
Cells and viruses
Monocytes were isolated from buffy coat from healthy
blood donors by positive selection on Monocyte Enrich-
ment Cocktail (Stemcell, Tukwila, WA) and Lymphoprep
(Stemcell) density gradient centrifugation with SepMate-50
(Stemcell). MDMs were generated by culturing monocytes
with 100 ng/ml granulocyte-macrophage colony-stimu-
lation factor for 5 days. 293T and HeLa cells were cultured
in DMEM (Gibco-BRL, Rockville, MD) supplemented
with 10% (V/V) fetal bovine serum (FBS) (Gibco-BRL).
HIV-189.6 and HIV-1NLAD-8 strains were produced in 293T
cells. Vesicular stomatitis virus G glycoprotein (VSV-G)-
pseudotyped viruses were produced in 293T cells cotrans-
fected with reporter virus plasmid and VSV-G using the
calcium-phosphate method. The culture supernatants were
collected and subjected to quantification of HIV-1 particle
yields by p24CA antigen capture enzyme-linked immuno-
sorbent assay (ELISA) (Zepto Metrix, Buffalo, NY). Mono-
cyte isolation and treatment were approved by the Ethics
Committee at the Yokohama City University School of
Medicine.
In vitro protein production
A total of 287 cDNAs encoding human protein kinases
were constructed as described previously [23]. The protein
production method has also been described previously
[55-57]. Briefly, DNA templates containing a biotin-liga-
ting sequence were amplified by split-PCR using cDNAs
and corresponding primers, and then used with the Gen-
Decoder protein production system (Cell Free Science,
Ehime, Japan). For HIV-1 Gag protein synthesis, Gag genes
derived from the pNL4-3 proviral plasmid [58] were
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Germ Expression kit (Cell Free Science) in accordance with
the manufacturer’s instructions.
Alphascreen-based protein-protein interaction assays
AlphaScreen assays were performed as described pre-
viously [23]. All recombinant proteins used here was syn-
thesized using a wheat germ based cell-free system as
described above. For each protein kinase, 1 μl of crude re-
combinant biotinylated construct from the human kinase
library was incubated with 1 μl of crude GST-Gag or
GST-DHFR in 10 μl of kinase assay buffer (100 mM Tris–
HCl pH8.0, 10 mM MgCl2, 0.1% Tween20, 0.1% BSA) at
37°C for 1 h in one well of a 384-well Optiplate (Perkin
Elmer, Foster City, CA. In accordance with the AlphaScreen
IgG (protein A) detection kit (Perkin Elmer) instruction
manual, 15 μl of detection mixture containing 100 mM
Tris–HCl pH 8.0, 0.01% Tween-20, 1 mg/ml BSA, 5 μg/ml
Anti-FLAG antibody (GE healthcare, Buckinghamshire,
UK), 5 ng streptavidin-coated donor beads and 5 ng anti-
IgG (protein A) acceptor beads were added to each well
followed by incubation at 26°C for 1 h. AlphaScreen sig-
nals from the mixture were detected using an EnVision
device (PerkinElmer) with the AlphaScreen signal detec-
tion program.
In vitro kinase assays
Biotinylated GST-Gag proteins were synthesized in wheat
germ cell-free extracts as described above. The synthe-
sized GST-Gag proteins were then purified using strep-
tavidin conjugated magnet beads (Promega). The purified
proteins on the beads were then incubated with recombi-
nant aPKCiota (Cell Signaling Technology) in a 50 μl reac-
tion mixture containing 20 mM Tris–HCl pH 7.5, 1 mM
EDTA, 1 mM dithiothreitol, 150 mM NaCl, 5 mM MgCl2,
0.05% Tween-20, 100 μM ATP and 2 μCi [γ-32P] ATP.
The reaction mixture was then incubated for 1 h at 37°C,
and the products were subjected to electrophoresis on
10% SDS polyacrylamide gels and were detected with an
image guider (BAS2500; Fujifilm, Tokyo, Japan).
Western blotting
Cells were harvested at the indicated post-treatment time
points with doxycycline, washed with phosphate-buffer
saline (PBS), and treated with lysis buffer (0.02% sodium
dodecyl sulfate [SDS], 0.5% Triton X-100, 300 mM NaCl,
20 mM Tris–HCl [pH 7.6], 1 mM EDTA, 1 mM dithio-
threitol) for 20 min on ice. Multiple protease inhibitors,
200 μM sodium vanadate and 20 mM sodium fluoride
were then added to the buffer. The samples were cen-
trifuged at 18,000 g for 10 min at 4°C, and clarified cell
extracts were assayed for protein concentration using a
Bio-Rad kit. Equal amounts of proteins (20 ~ 50 μg) were
resolved by SDS-10% polyacrylamide (acrylamide, 29.2;bisacrylamide, 0.8) gel electrophoresis (SDS-PAGE) in
running buffer (250 mM glycine, 25 mM Tris, 0.1% SDS).
The separated proteins were transferred to polyvinylidene
difluoride membrane. The membranes were washed with
blotting buffer (TBS containing 0.1% Tween 20) and
blocked in 10% low-fat powdered milk in blotting buffer
for 1 h at room temperature. Primary antibodies were
added at appropriate dilutions in 3% bovine serum albu-
min in blotting buffer and rocked overnight at 4°C. The
membranes were then further washed in blotting buffer
and incubated with a horseradish peroxidase-conjugated
secondary antibody at room temperature for 1 h. Target
proteins were detected with an enhanced chemilumine-
scence detection system (GE Healthcare). Images were
processed using Fluor Chem FC2 (Alpha Innotech Corp.
Tokyo, Japan) with a cooled charge-coupled device (CCD)
camera and assembled using Adobe Photoshop CS5
Extended.
Identification of phosphorylation sites on HIV-1 gag by
mass spectrometry
Samples were separated by SDS-PAGE (12.5%) and the gel
was stained with Coomassie brilliant blue (CBB). Gag was
excised from the stained gel and digested with trypsin in
50 mM NH4HCO3 (pH 8.0) for 12 h at 37°C. Phospho-
peptides were enriched using Titansphere® Phos-TiO
Kit (GLsciences, Tokyo, Japan), in accordance with the
manufacturer’s instructions. The enriched phosphopep-
tides were then analyzed by MALDI-TOF/TOF-MS (4800
proteomics analyzer, AB SCIEX, Foster City, CA). The
resulting raw MS spectrum was processed using the 4000
Series Explorer Software (AB SCIEX, Framingham, MA)
to generate Mascot generic format. The obtained MS and
MS/MS data were then searched against the SwissProt
database (January, 2013; 538849 sequences) using Mascot
version 2.4.1 software (Matrix Science, London, UK), to
identify proteins and protein modification. The search
parameters were as follows: trypsin digestion with two
missed cleavages permitted, variable modifications (oxida-
tion of Met and phosphorylation of Ser, Thr, and Tyr),
peptide mass tolerance for MS data ±0.15 Da, and frag-
ment mass tolerance ±0.3 Da. Phosphopeptides were
determined primarily using the Mascot program and were
confirmed manually through raw MS/MS sequence data
checking for the neutral loss of the phosphate group
(−98).
Analysis of structural data and structural model
construction
The 3D structure of Alix with wild-type Gag-p6 was
predicted by homology modeling using Molecular
Operating Environment (MOE) (Chemical Computing
Group, Canada). X-ray crystal structure of Gag-p6-Alix
(Protein Data Bank [PDB] code: 2R02) was used as
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AMBER ff99 force field and the GB/VI implicit solvent
energy function [59]. Next, on the basis of the predicted
structural model of Alix with wild-type Gag-p6, 3D
structures of Alix with Gag-p6S487A and phosphorylated
Gag-p6-Ser487 were constructed using Molecular Builder
in MOE.
3D structures of Vpr with wild-type Gag-p6, Gag-
p6Ser487A, and phosphorylated Gag-p6-Ser487 were also
predicted by docking simulations with ASEdock module
in MOE, because of no complex structure of Gag-p6-Vpr.
The complex structure was estimated with a nuclear
magnetic resonance (NMR) structure of Vpr (PDB code:
1M8L [60]) and a NMR structure around helix II domain
of Gag-p6 (Gag Y483 to S494) (PDB code: 2C55). Substi-
tution and phosphorylation at Gag S487 were achieved
with the Molecular Builder. Energy calculations in the
docking simulations were achieved with the same force
field as that for Gag-p6-Alix.
Finally, all of the constructed complex structures were
thermodynamically optimized with energy minimization,
to remove unfavorable steric contacts.
Bimolecular fluorescence complementation assay (BiFC)
To detect interaction of Gag with Vpr, we used the BiFC
technique. Briefly, two fragments of Kusabira-Green (KG)
fluorescent protein are brought together by the interaction
of two proteins fused to these fragments, thus allowing
specific detection of interaction in living cells (Amalgaam).
Vpr or Vpr Q44E were cloned into phmKGN-MN and
Gag or GagSer487A into phmKGC-MC. 293T cells were
cotransfected with 0.7 μg of the Vpr construct and 0.5 μg
of the Gag construct. Two days post transfection, cells
were harvested and then subjected to the flow cytometry
for measuring BiFC signal as reported previously [34].
Immunoprecipitation
Cells were lysed in Lysis buffer containing 50 mM Tris–
HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM DTT
with Complete protease inhibitor cocktail (Roche Molecular
Biochemicals, Indianapolis, IN) and PhosSTOP phosphat-
ase inhibitor cocktail (Roche Molecular Biochemicals).
Lysate were cleared by centrifugation at 12,000 × g for
15 min, followed by pull down using with anti-Flag M2
affinity Gel (Sigma). Samples were separated by SDS-
PAGE and analysed by Western blot analyses.
Single-cycle virus release assays
For infection-based assays, cells were infected with VSV-
G-pseudotyped HIV-1 at an moi (multiplicity of infec-
tion) of 0.01 or 0.2 for eight hours and cultured for two
days. In experiments using kinase inhibitors, cells were
treated with each inhibitor at 12 h before virus infection.
Virus-containing supernatants were harvested and filteredto remove cell debris, and viral p24 antigens were mea-
sured using an ELISA kit (Zepto Metrix). The cell lysates
were prepared using HBST buffer (10 mM HEPES,
pH 7.4, 150 mM NaCl, 0.5% Triton X-100) containing a
protease inhibitor cocktail (Roche). Immunoblotting as-
says and the antibodies used have been described previ-
ously [61]. The culture supernatants and cell lysates were
subjected to p24 ELISA or immunoblotting assays, as de-
scribed above.HIV-1 production assay
Primary human macrophages were infected with HIV-189.6
or HIV-1NLAD-8 virus. Two days post-infection, these cells
were washed with PBS to eliminate the presence of virus.
After washing, the cells were cultured either in media
alone or media containing aPKC inhibitor. Infected macro-
phages were cultured for 12 days, during which time viral
supernatants were collected and fresh media with inhi-
bitors was also added every three days. The p24 levels con-
tained in each viral supernatant sample was monitored
using p24 ELISA (Zepto Metrix) in accordance with the
manufacturer’s protocol.Competing interests
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